Detalhe da pesquisa
1.
Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Curr Top Microbiol Immunol
; 405: 79-97, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-25702159
2.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol
; 17(2): 212-223, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26727163
3.
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Lancet Oncol
; 12(12): 1125-33, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22019520
4.
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.
Mol Ther
; 16(5): 985-94, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18388930
5.
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
PLoS One
; 10(7): e0132568, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26207902